Compare Bristol-Myers Squibb Co (BMY) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs PulteGroup, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while PulteGroup, Inc. trades at $123.99 (market cap $23.73B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.9× PulteGroup, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PHM | |
|---|---|---|
Market Cap | $116.30B | $23.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $142.56 |
52-Week Low | $42.60 | $108.00 |
Enterprise Value | $152.24B | $23.69B |
Dividend Yield | 4.42% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PulteGroup (PHM) trades at $123.75, down 0.8% on the day, with a bullish technical signal but mixed recent earnings. The stock shows strong profitability with a 12.14% net margin and attractive valuation at a P/E of 11.97. Recent news highlights new community developments and market sensitivity to mortgage rates. Cash flow trends improved in 2025 with net cash flow of $355 million.
Outlook remains cautiously optimistic with a consensus price target of $146, implying 18% upside. Risks include housing affordability pressures and recent earnings misses. Analyst sentiment is balanced with 45% buy ratings. The stock's valuation and dividend support a constructive view amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
